These findings support the potential utility of MDM2 expression as a predictive biomarker even in locoregional therapeutic settings and warrant further exploration of MDM2-targeted agents to enhance ILP efficacy in melanoma [44]. The gene discussed is MDM2; the disease is melanoma.